

| Catalog No. | ZV678012 |
|---|---|
| Description |
Recombinant Tupaia chinensis IL31 Protein, N-His (ZV678012) expressed in E. coli. Purity: >90% as determined by SDS-PAGE..
Highlights
|
| Expression system | E. coli |
| Accession | XP_006149404.1 |
| Protein length | Leu61-Ala203 |
| Applications | ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress |
| Species | Tupaia chinensis (Chinese tree shrew) |
| Nature | Recombinant |
| Endotoxin level | Remove endotoxin and sterilization is required for cell assay. |
| Purity | >90% as determined by SDS-PAGE. |
| Predicted molecular weight | 18.56 kDa |
| Form | Lyophilized |
| Storage buffer | Lyophilized from a solution in PBS pH 7.4, 1 mM EDTA, 4% Trehalose, 1% Mannitol. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Reconstitution | Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details. |
| Shipping | In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Background | Dovanvetmab (ZTS-00521505) is an IgG1-κ antibody targeting Felcat IL31. Mainly expressed by CHO (Chinese Hamster Ovary) cells. • The IL-4, IL-13 and IL-31 pathways in atopic dermatitis., PMID:34106037 • IL-31-dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis., PMID:37831760 • Interleukin-31: The "itchy" cytokine in inflammation and therapy., PMID:33629401 • A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1., PMID:24373353 • Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis., PMID:38117036 • Nemolizumab: First Approval., PMID:35834124 • Nemolizumab: An Innovative Biologic Treatment to Control Interleukin 31, a Key Mediator in Atopic Dermatitis and Prurigo Nodularis., PMID:35842249 • The Cytokine TGF-β Induces Interleukin-31 Expression from Dermal Dendritic Cells to Activate Sensory Neurons and Stimulate Wound Itching., PMID:32673566 • Pruritus as a Distinctive Feature of Type 2 Inflammation., PMID:33807098 • Targeting Interleukin-31 in Prurigo., PMID:37888922 |
| Note | For research use only |



Contact us for custom quotes, bulk requests and any other issues.
Mail: [email protected]
Quick access
Contact Us
+86-27-65523339
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский